Etazolate

DB05881InvestigationalSmall molecule

EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

Mechanism: EHT 0202 was discovered to play a role in protecting neurons in pharmacological models of neuronal cell death. ExonHit identified RNA isoforms produced by alterations of splicing specifically taking place in neurodegenerative disease models. These isoforms were identified using DATAS(TM), ExonHit's proprietary gene profiling technology. DATAS(TM), stands for Differential Analysis of Transcripts with Alternative Splicing.
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease and neurologic disorders.Curator reviewed
Also known as: 1H-PYRAZOLO(3,4-B)PYRIDINE-5-CARBOXYLIC ACID, 1-ETHYL-4-((1-METHYLETHYLIDENE)HYDRAZINO)-, ETHYL ESTER
Code names: EHT-0202

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etazolate, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.